Literature DB >> 19923808

Blocking pro-cell-death signal pathways to conserve hearing.

Christine T Dinh1, Thomas R Van De Water.   

Abstract

The programmed cell death of stress-damaged auditory hair cells can occur through a variety of signal pathways, and therapeutic modalities that block pro-cell-death pathways are being developed and evaluated for hearing preservation. Because of their ability to have both anti-inflammatory and anti-apoptotic actions, corticosteroids have long been used to protect against several types of acute sensorineural hearing loss. Other anti-apoptotic drugs that target the mitogen-activated protein kinase (MAPK)/c-Jun-N terminal kinase (JNK) signal cascade, such as D-JNKI-1 (AM-111) and SP600125, have produced promising results both in vitro and in laboratory animal studies, with AM-111 showing promise in preliminary clinical trials. Antioxidant drugs, e.g. sodium thiosulfate, N-acetylcysteine, and D-methionine, have been shown in animal studies to attenuate permanent threshold shifts in hearing by reducing oxidative stress. In addition to reviewing selected therapeutic trends for the conservation of hearing, we review our experiences with dexamethasone and D-JNKI-1 and report results from our current research. (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19923808     DOI: 10.1159/000241895

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  14 in total

1.  The design and screening of drugs to prevent acquired sensorineural hearing loss.

Authors:  Debashree Mukherjea; Leonard P Rybak; Kelly E Sheehan; Tejbeer Kaur; Vickram Ramkumar; Sarvesh Jajoo; Sandeep Sheth
Journal:  Expert Opin Drug Discov       Date:  2011-03-15       Impact factor: 6.098

2.  Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.

Authors:  Oksana Polesskaya; Lisa L Cunningham; Shimon P Francis; Anne E Luebke; Xiaoxia Zhu; David Collins; Olga N Vasilyeva; Julie Sahler; Emily A Desmet; Harris A Gelbard; Sanjay B Maggirwar; Joseph P Walton; Robert D Frisina; Stephen Dewhurst
Journal:  Hear Res       Date:  2010-10-27       Impact factor: 3.208

Review 3.  Otoprotectants: From Research to Clinical Application.

Authors:  Colleen G Le Prell
Journal:  Semin Hear       Date:  2019-04-26

Review 4.  [Intracochlear drug delivery in combination with cochlear implants : Current aspects].

Authors:  S K Plontke; G Götze; T Rahne; A Liebau
Journal:  HNO       Date:  2016-11       Impact factor: 1.284

5.  Cytomegalovirus-induced sensorineural hearing loss with persistent cochlear inflammation in neonatal mice.

Authors:  Scott J Schachtele; Manohar B Mutnal; Mark R Schleiss; James R Lokensgard
Journal:  J Neurovirol       Date:  2011-03-18       Impact factor: 2.643

Review 6.  Biological therapies in otology.

Authors:  A Roemer; H Staecker; S Sasse; T Lenarz; A Warnecke
Journal:  HNO       Date:  2017-08       Impact factor: 1.284

7.  [Biological therapies in otology. German version].

Authors:  A Roemer; H Staecker; S Sasse; T Lenarz; A Warnecke
Journal:  HNO       Date:  2017-07       Impact factor: 1.284

8.  Antioxidants L-carnitine and D-methionine modulate neuronal activity through GABAergic inhibition.

Authors:  Calvin Wu; Kamakshi V Gopal; Ernest J Moore; Guenter W Gross
Journal:  J Neural Transm (Vienna)       Date:  2014-02-15       Impact factor: 3.575

9.  The JNK inhibitor XG-102 protects against TNBS-induced colitis.

Authors:  Kirstin Reinecke; Sevgi Eminel; Franziska Dierck; Wibke Roessner; Sabine Kersting; Ansgar Michael Chromik; Olga Gavrilova; Ale Laukevicience; Ivo Leuschner; Vicki Waetzig; Philip Rosenstiel; Thomas Herdegen; Christian Sina
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240

10.  Minocycline protection of neomycin induced hearing loss in gerbils.

Authors:  Alan M Robinson; Irena Vujanovic; Claus-Peter Richter
Journal:  Biomed Res Int       Date:  2015-04-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.